Lung cancer remains the leading cause of cancer-related morbidity worldwide. Pulmonary was the most common site of malignant tumors. The treatment of advanced NSCLC and pulmonary metastases has changed from chemotherapy to targeted therapy and immunotherapy. Meanwhile, local ablative therapies have also been widely used in clinical settings for lung cancer treatment. Local ablative therapy could be an alternative treatment for patients unfit for radical surgery due to cardiovascular and pulmonary diseases in primary lung cancer. For patients with pulmonary oligo-metastases, local ablative therapy could be a curable treatment. Moreover, the combination of local ablative therapy and systemic treatments have improved patients’ responses and prolonged survival. This Research Topic aimed to provide a forum for the recent advances of local ablative therapy on primary and secondary lung cancers.
For this Research Topic, we would like to bring together submissions of Original Research and Review articles on the recent advances and novel methods on local ablative therapy in the treatment of lung cancers. Topics of interest include, but is limited to, the following aspects:
• Local ablative therapy alone in the treatment of lung cancer
• Local ablative therapy in combination with immunotherapy for lung cancer treatment
• Local ablative therapies for early-stage NSCLC patients with contradiction to radical surgery
• Local ablative therapies for GGO-dominant lung cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Lung cancer remains the leading cause of cancer-related morbidity worldwide. Pulmonary was the most common site of malignant tumors. The treatment of advanced NSCLC and pulmonary metastases has changed from chemotherapy to targeted therapy and immunotherapy. Meanwhile, local ablative therapies have also been widely used in clinical settings for lung cancer treatment. Local ablative therapy could be an alternative treatment for patients unfit for radical surgery due to cardiovascular and pulmonary diseases in primary lung cancer. For patients with pulmonary oligo-metastases, local ablative therapy could be a curable treatment. Moreover, the combination of local ablative therapy and systemic treatments have improved patients’ responses and prolonged survival. This Research Topic aimed to provide a forum for the recent advances of local ablative therapy on primary and secondary lung cancers.
For this Research Topic, we would like to bring together submissions of Original Research and Review articles on the recent advances and novel methods on local ablative therapy in the treatment of lung cancers. Topics of interest include, but is limited to, the following aspects:
• Local ablative therapy alone in the treatment of lung cancer
• Local ablative therapy in combination with immunotherapy for lung cancer treatment
• Local ablative therapies for early-stage NSCLC patients with contradiction to radical surgery
• Local ablative therapies for GGO-dominant lung cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
